FDC Ltd
FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]
- Market Cap ₹ 7,732 Cr.
- Current Price ₹ 475
- High / Low ₹ 659 / 402
- Stock P/E 24.4
- Book Value ₹ 141
- Dividend Yield 1.05 %
- ROCE 18.4 %
- ROE 14.2 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Company has a low return on equity of 11.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty Microcap 250 BSE 250 SmallCap Index BSE 400 MidSmallCap Index BSE 500 BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
772 | 845 | 888 | 994 | 1,013 | 1,074 | 1,089 | 1,341 | 1,331 | 1,525 | 1,784 | 1,943 | 2,072 | |
591 | 638 | 690 | 765 | 769 | 841 | 860 | 1,038 | 997 | 1,271 | 1,533 | 1,604 | 1,715 | |
Operating Profit | 181 | 207 | 199 | 229 | 243 | 233 | 229 | 304 | 334 | 254 | 251 | 339 | 357 |
OPM % | 23% | 24% | 22% | 23% | 24% | 22% | 21% | 23% | 25% | 17% | 14% | 17% | 17% |
46 | 39 | 46 | 39 | 44 | 45 | 42 | 57 | 95 | 76 | 50 | 102 | 108 | |
Interest | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 4 | 4 | 4 |
Depreciation | 28 | 25 | 39 | 34 | 35 | 35 | 33 | 37 | 38 | 37 | 39 | 40 | 45 |
Profit before tax | 198 | 218 | 204 | 232 | 252 | 241 | 237 | 320 | 388 | 289 | 258 | 396 | 415 |
Tax % | 22% | 38% | 27% | 27% | 25% | 28% | 28% | 25% | 22% | 25% | 25% | 23% | |
155 | 135 | 148 | 169 | 189 | 174 | 170 | 240 | 301 | 216 | 194 | 305 | 317 | |
EPS in Rs | 8.49 | 7.61 | 8.33 | 9.48 | 10.60 | 9.95 | 9.74 | 14.03 | 17.85 | 12.82 | 11.70 | 18.75 | 19.44 |
Dividend Payout % | 26% | 30% | 27% | 24% | 21% | 0% | 0% | 6% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 12% |
3 Years: | 13% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 1% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 16% |
3 Years: | 16% |
1 Year: | 14% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 13% |
3 Years: | 12% |
Last Year: | 14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 | 16 |
Reserves | 766 | 827 | 919 | 1,065 | 1,252 | 1,259 | 1,428 | 1,530 | 1,717 | 1,940 | 1,965 | 2,081 | 2,275 |
3 | 3 | 2 | 1 | 1 | 1 | 1 | 15 | 15 | 32 | 28 | 21 | 20 | |
179 | 211 | 210 | 182 | 197 | 228 | 194 | 250 | 207 | 281 | 333 | 350 | 376 | |
Total Liabilities | 966 | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,688 |
289 | 284 | 393 | 675 | 678 | 674 | 682 | 674 | 689 | 705 | 699 | 680 | 805 | |
CWIP | 7 | 18 | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 105 | 198 | 261 | 143 |
Investments | 416 | 417 | 489 | 325 | 491 | 471 | 585 | 665 | 790 | 886 | 806 | 843 | 1,066 |
254 | 340 | 237 | 246 | 293 | 348 | 360 | 451 | 458 | 575 | 640 | 684 | 674 | |
Total Assets | 966 | 1,059 | 1,148 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,688 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
150 | 150 | 128 | 174 | 154 | 150 | 112 | 250 | 207 | 162 | 155 | 221 | |
-107 | -55 | -89 | -73 | -144 | 21 | -121 | -98 | -77 | -145 | 11 | -17 | |
-63 | -75 | -48 | -97 | 0 | -169 | -0 | -142 | -129 | -10 | -180 | -202 | |
Net Cash Flow | -20 | 19 | -9 | 4 | 11 | 1 | -8 | 10 | 1 | 7 | -14 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 20 | 26 | 25 | 23 | 27 | 28 | 29 | 34 | 30 | 20 | 25 | 22 |
Inventory Days | 117 | 116 | 132 | 134 | 148 | 166 | 184 | 180 | 189 | 210 | 183 | 216 |
Days Payable | 72 | 90 | 94 | 84 | 81 | 101 | 82 | 101 | 68 | 94 | 99 | 103 |
Cash Conversion Cycle | 66 | 51 | 64 | 72 | 94 | 93 | 131 | 113 | 152 | 135 | 109 | 135 |
Working Capital Days | 24 | 2 | 11 | 21 | 23 | 29 | 45 | 41 | 50 | 47 | 49 | 54 |
ROCE % | 23% | 25% | 21% | 22% | 21% | 19% | 17% | 21% | 22% | 15% | 13% | 18% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - Certificate for securities dematerialized for Q4 2024.
-
Intimation Of Change In Name Of Company'S Registrar And Share Transfer Agent (RTA)
2 Jan - Change of name of Company’s RTA to MUFG Intime.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
26 Dec - Issue of duplicate share certificates for lost originals.
- Closure of Trading Window 26 Dec
-
Intimation Regarding Approval Received From US FDA For ANDA- Cefixime 400 Mg Tablets
18 Dec - Final approval for Cefixime 400 mg Tablets from US FDA.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2023Transcript PPT REC
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptPPT
-
Dec 2021TranscriptPPT
-
Jun 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]